From Name:
From Email:
To Name:
To Email:

Optional Message:

Pharma 2018: Expect More M&As, USFDA Reinspections in a Normalized Year

from 12/28/17, Business Today

The expectation is that 2018/19 could be the first normalized year for pharma after a while and the sector could show growth considering that the base is likely to be low by the end of FY18. And there may be more acquisitions. Plus, many of the leading companies will see their facilities come in for re-inspection by the U.S. drug regulator — be it Sun Pharma's Halol, Dr. Reddy's Duvvada and Srikakulam and Lupin's Goa and Indore facilities. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063